Abstract 1717TiP
Background
Systemic therapy for renal cell carcinoma (RCC) relies on two classes of agents: vascular endothelial growth factor tyrosine kinase inhibitors (VEGFR TKI) and immune checkpoint inhibitors (ICI) targeting either PD1 or CTLA4. ICI based combination therapy is standard-of-care for clear cell RCC with either ICI-ICI or ICI-VEGFR TKI. However, no head-to-head comparison have been performed between the two approaches and patients are treated based on physician decision without biomarker to guide treatment selection. PDL1 staining may help select patient who derive benefit to upfront ICI-ICI strategy.
Trial design
The CARE1 study is a pragmatic phase III international multicenter randomized clinical trial funded by the European Union’s Horizon Europe research and innovation program under grant agreement No 101104801, PHRC grant N° K2022-2023 provided by National Cancer Institute in France, Gustave Roussy and CRIS Cancer Foundation Real-Life Trials in Oncology Programme. The main objective of CARE1 is to demonstrate that ICI-ICI improves overall survival over ICI-VEGFR TKI in PDL1 positive patients with metastatic clear-cell renal cell carcinoma in the first line setting, and conversely to demonstrate that ICI-VEGFR TKI improves overall survival over ICI-ICI in PDL1 negative patients. PDL1 positivity is defined locally as ≥1% of stained tumor cells. Patients will be randomized 1:1 to receive ICI-ICI or ICI-TKI. Secondary endpoints are progression-free survival (PFS) – PFS will be a co-primary endpoint specifically in the PDL1 negative population –, objective response rate according to RECIST 1.1, duration of treatment, time-to-treatment discontinuation, treatment-free survival, time to subsequent systemic anticancer therapy, quality of life, safety and cost-effectiveness. A comprehensive translational program including tissue and circulating biomarkers is embedded into the CARE1 study. The trial is currently recruiting and 1200 patients will be enrolled across 8 European countries.
Clinical trial identification
EUCT 2023-503317-29-00; NCT0636463.
Editorial acknowledgement
Legal entity responsible for the study
Gustave Roussy.
Funding
European Union’s Horizon Europe research and innovation program under grant agreement No 101104801; National Cancer Institute in France; Gustave Roussy Foundation; Cris Cancer Foundation.
Disclosure
L. Albiges: Financial Interests, Institutional, Other, Consulting: Astellas, BMS, Eisai, Ipsen, Janssen, MSD, Novartis, Pfizer, Roche, Merck, Amgen; Financial Interests, Personal, Other, Honoraria: Novartis; Non-Financial Interests, Principal Investigator, Clinical trial steering committee: Pfizer, BMS, AVEO, AstraZeneca, MSD; Non-Financial Interests, Principal Investigator: Ipsen; Non-Financial Interests, Other, Clinical trial steering committee: Roche, Exelixis; Non-Financial Interests, Member: ASCO; Non-Financial Interests, Other, Medical Steering Committee: Kidney Cancer Association; Non-Financial Interests, Other, Member of the Renal Cell Carcinoma Guidelines Panel: European Association of Urology (EAU). C. Suarez Rodriguez: Financial Interests, Personal, Invited Speaker: Astellas Pharma, Bristol Myers Sqquib (Inst), Ipsen, Hoffmann-La Roche Ltd, Merck; Financial Interests, Personal, Advisory Board: Bristol Myers Sqquib (Inst), Ipsen, Hoffmann-La Roche Ltd, Merck Sharp and Dohme, Eisai; Financial Interests, Institutional, Funding: Ipsen; Financial Interests, Institutional, Research Grant: Pfizer. G. Procopio: Financial Interests, Personal, Advisory Board, consultant fees: Astellas, AstraZeneca, Amgen, Boehringer, Bayer, Brystol Myers Squibb, Ipsen, Janssen, Eisai, Janssen Cilag, Merck Sharp & Dohme, Merck, Pfizer, Roche, Eli Lilly; Financial Interests, Personal, Other, workgroup: Menarini Group; Financial Interests, Institutional, Research Grant, research funding for no profit clinical trial: Ipsen, Gilead, MSD, Janssen. A. Bex: Financial Interests, Institutional, Advisory Board, Online advisory board: Ipsen; Financial Interests, Institutional, Other, Membership of a DMSB of a Merck led trial (terminated in 2023): Merck; Financial Interests, Institutional, Research Grant, Restricted educational grant for an investigator initiated trial of neoadjuvant therapy in high risk renal cancer: Pfizer; Non-Financial Interests, Principal Investigator, Steering committee member and PI in an adjuvant trial: Roche/Genentech; Non-Financial Interests, Principal Investigator, Steering committee member and local investigator in an adjuvant trial: BMS; Non-Financial Interests, Advisory Role, Medical Steering committee member to advise the patient advocacy group on medical topics and strategy: International Kidney Cancer Coalition, Kidney Cancer Association. V. Gruenwald: Financial Interests, Personal, Invited Speaker: Amgen, Astellas, AstraZeneca, BMS, Eisai, Ipsen, Janssen-Cilag, MSD, Merck Serono, Novartis, Pfizer, Gilead; Financial Interests, Personal, Advisory Board: Apogepha, BMS, Debiopharm, Eisai, MSD, Merck Serono, Oncorena, PCI Biotech, Pfizer, Roche, Cureteq, Synthekine; Financial Interests, Personal, Stocks/Shares: BMS, MSD, AstraZeneca, bicycle; Financial Interests, Institutional, Steering Committee Member: BMS, Novartis; Financial Interests, Institutional, Research Grant: Ipsen, MSD, Pfizer, BMS; Financial Interests, Personal and Institutional, Steering Committee Member: Eisai, Ipsen; Non-Financial Interests, Member: ASCO, German medical Oncology and Hematology Society; Non-Financial Interests, Advisory Role: German Cancer Society; Non-Financial Interests, Leadership Role: Working Group medical oncology; Other, Travel support to ESMO 2022: Pfizer; Other, Travel support for meeting: Merck Serono; Other, Travel Support ASCO GU 2024: Ipsen; Other, Travel Support: Janssen Cilag. M. Schmidinger: Financial Interests, Personal, Advisory Board, advisory boards or lectures: BMS, MSD, Ipsen; Financial Interests, Personal, Advisory Board, Advisory board or lectures: Eisai; Financial Interests, Personal, Advisory Board: Exelixis; Financial Interests, Personal, Other, Travel support: Eusa; Financial Interests, Personal, Advisory Board, Advisor: Pfizer; Financial Interests, Institutional, Other, Research grant: Ipsen; Non-Financial Interests, Principal Investigator, trial investigator: MSD; Non-Financial Interests, Advisory Role, Steering Committee member: Exelixis. B. Melichar: Financial Interests, Personal, Advisory Board: Roche, BMS, MSD, Novartis, Merck Serono, E. Lilly, Pfizer, AstraZeneca. G.A. De Velasco Oria: Financial Interests, Personal, Advisory Board: Pfizer, Astellas, BMS, MSD, Ipsen, Bayer, AstraZeneca, Eisai; Financial Interests, Personal, Invited Speaker: Pfizer, Astellas, BMS, MSD, Roche, Ipsen, Merck, Novartis, Janssen, Bayer; Financial Interests, Institutional, Research Grant: Roche. A.R. Ferreira: Financial Interests, Personal, Advisory Board: Roche, Novartis, Merck Sharp & Dohme, Seagen; Financial Interests, Personal, Invited Speaker: Roche, Novartis, Gilead Sciences; Financial Interests, Personal, Full or part-time Employment: Resilience. N. Rioux-Leclercq: Financial Interests, Personal, Invited Speaker, Paid conferences: Amgen, AstraZeneca, BMS, Ipsen, Janssen, MSD. J. Bonastre: Financial Interests, Personal, Advisory Board, Scientific board: BMS, MSD, Janssen, Roche; Financial Interests, Institutional, Funding, Funding of the MICADO study: BMS. R. Flippot: Financial Interests, Institutional, Invited Speaker: Ipsen, Pfizer; Financial Interests, Institutional, Advisory Board: MSD (Merck Sharp Dohme), Eisai, Astellas, Bayer, Johnson & Johnson, Merck Serono; Financial Interests, Personal, Other, Travel Expenses: Bristol Myers Squibb; Financial Interests, Institutional, Coordinating PI: Bayer. B. Escudier: Financial Interests, Personal, Advisory Board: MSD, Ipsen, Oncorena. S. Foulon: Financial Interests, Institutional, Advisory Board, Participation to the advisory board (statistical advice) of an epidemiological study performed by Gilead on real world data (medico-administrative data): Review and validation of the study protocol, validation of the study population, as well as the review and validation of the results and of the study report: Gilead. T.B. Powles: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Myers Squibb, Exelixis, Incyte, Ipsen, Merck, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, Roche, MSD; Financial Interests, Personal, Other, Travel/Accommodation/Expenses: Roche, Pfizer, MSD, AstraZeneca, Ipsen; Financial Interests, Personal, Other, Sponsorship for Uromigos Podcast: Mashup Ltd; Financial Interests, Institutional, Other, honoraria: Gilead; Financial Interests, Institutional, Research Grant: AstraZeneca, Roche, Bristol Myers Squibb, Exelixis, Ipsen, Merck, MSD, Seattle Genetics, Novartis, Pfizer, Merck Serono, Astellas, Johnson & Johnson, Eisai; Financial Interests, Institutional, Other, Honoraria: Gilead. All other authors have declared no conflicts of interest.
Resources from the same session
1864P - Study on the real-life use of G-CSF in patients with lung cancer: Secondary data analysis from the French national cohorts KBP-2020-CPHG and ESCAP-2020-CPHG
Presenter: Didier Debieuvre
Session: Poster session 12
1865P - DEFENDOR special: Real-world use of pegylated granulocyte-colony stimulating factor in patients with gastrointestinal cancers
Presenter: Alexey Tryakin
Session: Poster session 12
1866P - Metabolic and quality of life changes with the use of dexamethasone pre-paclitaxel in patients with breast cancer
Presenter: VANESSA SCONTRE
Session: Poster session 12
1867P - Efficacy of lower dose of dexamethasone premedication in patient receiving docetaxel-based chemotherapy in preventing hypersensitivity reaction: A randomized controlled trial
Presenter: Sitthichai Chanmaniloet
Session: Poster session 12
1868P - Development and validation of a clinical prediction model for paclitaxel hypersensitivity reaction: Pac-HSR score
Presenter: Radasar Sukphinetkul
Session: Poster session 12
1869P - Risk factors for reduced relative dose intensity (RDI) in patients with solid tumors receiving chemotherapy (CT) and primary prolonged G-CSF prophylaxis by empegfilgrastim: Analysis of DEFENDOR study
Presenter: Anton Snegovoy
Session: Poster session 12
1870P - Safety and efficacy of cryotherapy in the prevention and treatment of chemotherapy-induced peripheral neuropathy
Presenter: Giovanna Giannecchini
Session: Poster session 12
1871P - Temperature-controlled hand-foot cooling combined with compression prevents chemotherapy-induced polyneuropathy (CIPN): A single center, prospective, real-world data collection
Presenter: Athina Kostara
Session: Poster session 12
1872P - Evaluation of PROMISE, grim, and cti scores for predicting 90-day mortality in hospitalized cancer patients: A retrospective analysis at a single center
Presenter: Galip Can Uyar
Session: Poster session 12
1873P - Thalidomide for the treatment of chemotherapy-induced night sweats in patients with pancreatic cancer
Presenter: Nan Lu
Session: Poster session 12